• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, April 1, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Artificial enzymes perform reactions on living cells

Bioengineer by Bioengineer
July 25, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Nature has evolved thousands of enzymes to facilitate the many chemical reactions that take place inside organisms to sustain life. Now, researchers have designed artificial enzymes that sit on the surfaces of living cells and drive reactions that could someday target drug therapies to specific organs. They report their results in the Journal of the American Chemical Society.

Metalloenzymes are a class of enzymes that contain a metal ion, such as zinc, iron or copper. The metal ion helps the enzyme speed up, or "catalyze," chemical reactions that would otherwise occur very slowly or not at all. Scientists would ultimately like to develop a method to produce therapeutic drugs only at the sites of specific cells or organs of the human body, which could reduce side effects, and enzymes could help them reach that goal. Wadih Ghattas, Jean-Pierre Mahy and their colleagues set their sights on engineering an artificial enzyme that could catalyze a useful reaction, called the Diels-Alder reaction, right on the surfaces of living cells. Chemists use this reaction to synthesize drugs, agrochemicals and many other molecules.

To make their artificial enzyme, the researchers began with a protein called the A2A adenosine receptor, which is naturally present on the surfaces of some cells in the body. They modified a molecule that binds to this receptor with a copper-containing chemical group that catalyzes the Diels-Alder reaction. When the researchers placed the resulting compound in a culture dish containing living human cells, it attached to the A2A adenosine receptors on the cells, forming an artificial enzyme. This enzyme catalyzed the Diels-Alder reaction with an up to 50 percent yield. The researchers say that in the future, artificial enzymes might be designed that bind to proteins found only on specific cell types, for example, cancer cells. Then, the enzyme could convert an inactive compound into a drug to selectively kill those cells.

###

The authors acknowledge funding from the French National Research Agency.

The abstract that accompanies this study is available here.

The American Chemical Society, the world's largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact [email protected].

Follow us on Twitter | Facebook

Media Contact

Katie Cottingham
[email protected]
301-775-8455
@ACSpressroom

http://www.acs.org

Share13Tweet8Share2ShareShareShare2

Related Posts

FOLR3 and Neutrophils Worsen Sepsis Inflammation

April 1, 2026

NIH Scientists Develop Pain-Relief Drug with Low Addiction Risk

April 1, 2026

Impact of AI-Powered Scribes on Clinician Time and Patient Visit Volume

April 1, 2026

Dorsoventral Hippocampus Reactivates After Aversive Sleep

April 1, 2026
Please login to join discussion

POPULAR NEWS

  • blank

    Revolutionary AI Model Enhances Precision in Detecting Food Contamination

    96 shares
    Share 38 Tweet 24
  • Imagine a Social Media Feed That Challenges Your Views Instead of Reinforcing Them

    1006 shares
    Share 398 Tweet 249
  • Promising Outcomes from First Clinical Trials of Gene Regulation in Epilepsy

    51 shares
    Share 20 Tweet 13
  • Popular Anti-Aging Compound Linked to Damage in Corpus Callosum, Study Finds

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

FOLR3 and Neutrophils Worsen Sepsis Inflammation

Manchester Professor Named Expert Reviewer for Government Nuclear Decommissioning Review

JMIR Publications Appoints Dr. Amy Shirong Lu as Editor-in-Chief of JMIR Serious Games

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 78 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.